Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial
30 August 2025 (10:15 - 11:00)
Organised by: 
Abstract
Slides
About the speaker
University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
6 More presentations in this session
Associate Professor L. Bikdelu (Mashhad, IR)
Doctor D. Sa (Funchal, PT)
Doctor D. Corsi (New Brunswick, US)
Doctor G. Bettencourt Abreu (Funchal, PT)
Access the full session
The Event
ESC Congress 2025
30 August 2025
10:15 CET
You may be interested in
Congress Session
Congress Presentation
